p53 codon 72 polymorphism as a progression index for bladder cancer

Oncology Reports

Volumn 27, Issue 4, 2012, Pages 1193-1199

  Lin, Hung Yu ^a,b   Huang, Chun Hsiung ^c   Yu, Tsan Jung ^a   Wu, Wen Jen ^c   Yang, Ming Chang ^d,e   Lung, For Wey ^d,f,g  

^a E DA HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^e NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^f TAIPEI CITY HOSPITAL   (Taiwan)

^g NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Cancer management index; Genotype Pro Pro; Prognosis

Indexed keywords

ADULT; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER GRADING; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CODON; FEMALE; GENETIC CORRELATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENT CANCER; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

ADULT; AGED; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CODON; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TAIWAN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 84863026479     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1610     Document Type: Article

References (21)

1. Lung FW, Lee TM, Shu BC and Chang FH: p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. J Cancer Res Clin Oncol 130: 728-732, 2004.
2. Furihata M, Kurabayashl A, Matsumoto M, et al: Frequent phosphorylation at serine 392 in overexpressed p53 protein due to missense mutation in carcinoma of the urinary tract. J Pathol 197: 82-88, 2002. (Pubitemid 34450167)
3. Chen WC, Tsai FJ, Wu JY, Wu HC, Lu HF and Li CW: Distributions of p53 codon 72 polymorphism in bladder cancer - proline form is prominent in invasive tumor. Urol Res 28: 293-296, 2000.
4. Lin H, Huang CH, Yu TJ, Wu WJ, Yang MC and Lung FW: p53 codon 72 polymorphism was associated with vulnerability, progression, but not prognosis of bladder cancer in Taiwanese population: an implication of structural equation modeling to manage risks of bladder cancer. Urol Int 86: 355-360, 2011.
5. Li CC, Chang TH, Wu WJ, et al: Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol 54: 1127-1134, 2008.
6. Chen YC, Xu L, Guo YL, et al: Polymorphisms in GSTT1 and p53 and urinary transitional cell carcinoma in south-western Taiwan: a preliminary study. Biomarkers 9: 386-394, 2004. (Pubitemid 40100628)
7. Lin HY, Huang CH, Wu WJ, et al: Mutation of the p53 tumor suppressor gene in transitional cell carcinoma of the urinary tract in Taiwan. Kaohsiung J Med Sci 21: 57-64, 2005. (Pubitemid 40477123)
8. Dumont P, Leu JI, Della Pietra AC III, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365, 2003. (Pubitemid 36278852)
9. Pim D and Banks L: p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108: 196-199, 2004. (Pubitemid 37541770)
10. Siddique M and Sabapathy K: Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25: 3489-3500, 2006. (Pubitemid 43901670)
11. Kuroda Y, Nakao H, Ikemura K and Katoh T: Association between the TP53 codon72 polymorphism and oral cancer risk and prognosis. Oral Oncol 43: 1043-1048, 2007. (Pubitemid 47532782)
12. Soulitzis N, Sourvinos G, Dokianakis DN and Spandidos DA: p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 179: 175-183, 2002. (Pubitemid 34215109)
13. Tada M, Furuuchi K, Kaneda M, et al: Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis 22: 515-517, 2001. (Pubitemid 32203833)
14. Storey A, Thomas M, Kalita A, et al: Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393: 229-234, 1998. (Pubitemid 28261713)
15. Park JS, Kim EJ, Lee JY, Sin HS, Namkoong SE and Um SJ: Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins. Int J Cancer 91: 822-827, 2001.
16. Horikawa Y, Nadaoka J, Saito M, et al: Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep 20: 49-55, 2008.
17. Falagas ME, Zarkadoulia EA, Ioannidou EN, Peppas G, Christodoulou C and Rafailidis PI: The effect of psychosocial factors on breast cancer outcome: a systematic review. Breast Cancer Res 9: R44, 2007.
18. Gidron Y and Ronson A: Psychosocial factors, biological mediators, and cancer prognosis: a new look at an old story. Curr Opin Oncol 20: 386-392, 2008.
19. Ghaemi SN: A Clinician's Guide to Statistics and Epidemiology in Mental Health. Cambridge University Press, Cambridge, 2009.
20. Boldrini L, Gisfredi S, Ursino S, et al: Effect of the p53 codon 72 and intron 3 polymorphisms on non-small cell lung cancer (NSCLC) prognosis. Cancer Invest 26: 168-172, 2008. (Pubitemid 351225472)
21. Zhang W, Jin MJ and Chen K: Association of p53 polymorphisms and its haplotypes with susceptibility of breast cancer. Zhejiang Da Xue Xue Bao Yi Xue Ban 36: 561-566, 2007.